Cholinesterase inhibitors in Alzheimer's disease: Preliminary recommendations for practice;Cholinesteraseremmers bij de ziekte van Alzheimer: Voorlopige aanbevelingen voor de praktijk

Nederlands Tijdschrift voor Geneeskunde

Volumn 142, Issue 38, 1998, Pages 2091-2096

  Verhey, F R J ^a   Heeren, T J ^b   Scheltens, P H ^c   Van Gool, W A ^d  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^d ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINESTERASE INHIBITOR; PLACEBO;

ALZHEIMER DISEASE; BEHAVIOR; CLINICAL PROTOCOL; COGNITION; DAILY LIFE ACTIVITY; DEMENTIA; HUMAN; PRACTICE GUIDELINE; REVIEW;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; CLINICAL PROTOCOLS; DRUG APPROVAL; FEMALE; HUMANS; MALE; MIDDLE AGED; NETHERLANDS; PATIENT SELECTION;

EID: 0032547478     PISSN: 00282162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (24)

1. Davis KL, Thal LJ, Gamzu ER, Davis CS, Woolson RF, Gracon SI, et al. A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. The Tacrine Collaborative Study Group. N Engl J Med 1992;327:1253-9.
2. Farlow M, Gracon SI, Hershey LA, Lewis KW, Sadowsky CH, Dolan-Ureno J. A controlled trial of tacrine in Alzheimer's disease. The Tacrine Study Group. JAMA 1992;268:523-9.
3. Knapp MJ, Knopman DS, Solomon PR, Pendlebury WW, Davis CS, Gracon SI. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. The Tacrine Study Group. JAMA 1994;271:985-91.
4. Knopman D, Schneider LS, Davis K, Talwalker S, Smith F, Hoover T, et al. Long-term tacrine (Cognex) treatment: effects on nursing home placement and mortality The Tacrine Study Group. Neurology 1996;47:166-77.
5. Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group. Neurology 1998; 50:136-45.
6. Cummings JF, Cyrus PA, Bieber F, Mas J, Orazem J, Gulanski B. Metrifonate treatment of the cognitive deficits of Alzheimer's disease. Neurology 1998;50:1214-21.
7. Morris JC, Cyrus PA, Orazem J, Mas J, Bieber F, Ruzicka B, et al. Metrifonate benefits cognitive, behavioral and global function in patients with Alzheimer's disease. Neurology 1998;50:1222-30.
8. Corey-Bloom J, Anand R, Veach J. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease. Int J Geriatr Psychopharmacol 1998; 1:55-65.
9. Kelly CA, Harvey RJ, Cayton H. Drug treatments for Alzheimer's disease. BMJ 1997;314:693-4.
10. Lovestone S, Graham N, Howard R, Guidelines on drug treatments for Alzheimer's disease. Lancet 1997;350:232-3.
11. American Psychiatric Association. Practice guideline for the treatment of patients with Alzheimer's disease and other dementias of late life. Am J Psychiatry 1997;154(5 Suppl):1-39.
12. Gool WA van. Efficacy of donepezil in Alzheimer's disease: fact or artefact? Neurology 1998 [ter perse].
13. Melzer D. New drug treatment for Alzheimer's disease: lessons for healthcare policy. BMJ 1998;316:762-4.
14. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry 1984;141:1356-64.
15. Schneider LS, Olin JT, Doody RS, Clark CM, Morris JC, Reisberg B, et al. Validity and reliability of the Alzheimer's disease cooperative study - clinical global impression of change. Alz Dis Assoc Disord 1997;11(Suppl):S22-32.
16. Knopman DS. Metrifonate for Alzheimer's disease. Is the next cholinesterase inhibitor better? Neurology 1998;50:1203-5.
17. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-44.
18. Schneider LS, Olin JT, Lyness SA, Chui HC. Eligibility of Alzheimer's disease clinic patients for clinical trials. J Am Geriatr Soc 1997;45:923-8.
19. Schneider LS, Tariot PN. Treatment of dementia. In: Salzman C, editor. Clinical geriatric psychopharmacology. Baltimore. Williams & Wilkins, 1998:510-42.
20. Derix MMA, Hofstede AB, Teunisse S, Hijdra A, Walstra GJM, Weinstein HC, et al CAMDEX-N: de Nederlandse versie van de Cambridge Examination for Mental Disorders of the Elderly met geautomatiseerde dataverwerking. Tijdschr Gerontol Geriatr 1991;22:143-50.
21. Roth M, Tym E, Mountjoy CQ, Huppert FA, Hendrie H, Verma S, et al. CAMDEX. A standardised instrument for the diagnosis of mental disorder in the elderly with special reference to the early detection of dementia. Br J Psychiatry 1986;149:698-709.
22. Blessed G, Tomlinson BE, Roth M. The association between quantitative measurements of dementia and of senile change in the cerebral grey matter of elderly subjects. Br J Psychiatry 1968;114:797-811.
23. Teunisse S, Derix MMA, Crevel H van. Assessing the severity of dementia. Patient and caregiver. Arch Neurol 1991;48:274-7.
24. Small GW, Rabins PV, Barly PP, et al. Diagnosis and treatment of Alzheimer disease and related disorders. Consensus statement of the American Association for Geriatric Psychiatry, the Alzheimer's Association & the American Geriatrics Society. JAMA 1997;278:1363-71.